Wilson Disease Drugs Market Size, Share and Trends Analysis Report, Forecast Period 2024-2031.
Wilson Disease Drugs Market Size, Share and Trends Analysis Report, Forecast Period 2024-2031.
Blog Article
The global Wilson disease drugs market is expected to grow at a CAGR of 4.5% during the forecast period. The market is anticipated to accelerate during the forecast period, owing to the emergence of several international and regional drug manufacturers that provides drugs such as chelators and minerals for Wilson treatment. Moreover, new drug launches by the key players are one of the prominent factors boosting the market growth. For instance, in August 2021, AstraZeneca’s Alexion rare disease unit cleared a phase 3 trial of ALXN1840 for the treatment of Wilson's disease. ALXN1840 improved copper mobilization from tissues. ALXN1840 was more than three times more effective than the standard treatment in mobilizing copper from tissues. In addition, limited infrastructural facilities and a lack of awareness in backward economies are expected to obstruct market growth. Additionally, the growing application of genetic testing in oncology and genetic diseases, coupled with the growing demand for direct-to-consumer testing has created a lucrative opportunity in coming years in the global Wilson disease drugs market.
Get Sample Copy of this Report at
https://www.omrglobal.com/request-sample/wilson-disease-drugs-market
Segmental Outlook
The global Wilson disease drugs market is segmented based on drug type, route of administration, and distribution channel. Based on drug type, the market is segmented into chelating agents, zinc, and tetrathiomolybdate. Based on the route of administration, the market is segmented into oral, parenteral, and others. Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others.
Penicillamine (Cupramine and Depen) and trientine (Syprine) are two chelating agents that are used for the treatment of Wilson's disease. Such medications remove copper from the body. However, Penicillamine may cause side effects compared to trientine. penicillamine side effects may include kidney problems, rash, fever, or bone marrow problems. Penicillamine may also decrease the activity of vitamin B6, and thus, vitamin B6 supplements may be recommended by the doctors along with penicillamine. Moreover, zinc prevents the intestines from absorbing copper. Zinc may be prescribed by the doctor as a maintenance treatment after chelating agents have removed extra copper from the body. In addition, doctors may also recommend zinc for people with Wilson's disease, however, who do not yet have symptoms. Stomach upset is the most common side effect of zinc.
full report of available
https://www.omrglobal.com/industry-reports/wilson-disease-drugs-market
By Drug Type (Chelating Agents, Zinc, and Tetrathiomolybdate), By Route of Administration (Oral, Parenteral, and Others),
By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others)
Market Players Outlook
The major companies operating in the global Wilson disease drug market include Bausch Health Co. Inc., Nobelpharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., and Kadmon Holdings, Inc. The market players are contributing significantly to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, new product launches, and partnerships, to stay competitive in the market. For instance, in May 2022, Orphalan SA declared US FDA approval of Cuvrior, a new salt of trientine (trientine tetrahydrochloride). Cuvrior is approved for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. Penicillamine is currently approved as a first-line treatment of Wilson’s disease in the US with about one-third of patients developing intolerance. Orphalan commercializes its trientine tetrahydrochloride product in Europe under the name of Cuprior and expects to launch Cuvrior, which has been granted Orphan Drug Designation by the FDA, in the US by early 2023. The approval follows the New Drug Application (NDA) submission for the company’s product in 2021.
Additionally, in August 2020, Dr Reddy’s Laboratories launched generic penicillamine capsules, to treat Wilson disease and cystinuria in the US market. penicillamine capsules are used by patients with severe, active rheumatoid arthritis, and the body failed to respond to an adequate trial of conventional therapy.
The Report Covers
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global Wilson disease drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market entry and market expansion strategies.
Competitive strategies by identifying ‘who-stands-where’ in the market.
For More Customized Data, Request for Report Customization
https://www.omrglobal.com/report-customization/wilson-disease-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404